ES2118087T3 - Composiciones inmunosupresoras. - Google Patents

Composiciones inmunosupresoras.

Info

Publication number
ES2118087T3
ES2118087T3 ES91915005T ES91915005T ES2118087T3 ES 2118087 T3 ES2118087 T3 ES 2118087T3 ES 91915005 T ES91915005 T ES 91915005T ES 91915005 T ES91915005 T ES 91915005T ES 2118087 T3 ES2118087 T3 ES 2118087T3
Authority
ES
Spain
Prior art keywords
compound
suppressor cell
immunosuppressive
cell inducing
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915005T
Other languages
English (en)
Inventor
Alison Mary Badger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of ES2118087T3 publication Critical patent/ES2118087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNA CELULA SUPRESORA NO ESPECIFICA (NS) QUE INDUCE COMPUESTOS Y UNA CELULA SUPRESORA NO-NS QUE INDUCE UN COMPUESTO INMUNOSUPRESIVO Y UN PORTADOR O DILUYENTE FARMACEUTICAMENTE ACEPTABLE, Y UN METODO DE INDUCCION DE UN EFECTO INMUNOSUPRESIVO EN MAMIFEROS, INCLUYENDO UN HUMANO, EN NECESIDAD DE ELLO QUE COMPRENDE ADMINISTRAR UNA DOSIS EFECTIVA DE UNA CELULA SUPRESORA NS QUE INDUCE UN COMPUESTO Y UNA CELULA SUPRESORA NO-NS QUE INDUCE UN COMPUESTO INMUNOSUPRESIVO EN TAL MAMIFERO.
ES91915005T 1990-08-10 1991-08-07 Composiciones inmunosupresoras. Expired - Lifetime ES2118087T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56582690A 1990-08-10 1990-08-10
US62245290A 1990-12-05 1990-12-05

Publications (1)

Publication Number Publication Date
ES2118087T3 true ES2118087T3 (es) 1998-09-16

Family

ID=27073977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915005T Expired - Lifetime ES2118087T3 (es) 1990-08-10 1991-08-07 Composiciones inmunosupresoras.

Country Status (12)

Country Link
EP (1) EP0542860B1 (es)
JP (1) JP2675194B2 (es)
KR (1) KR100215167B1 (es)
AT (1) ATE166228T1 (es)
AU (1) AU658577B2 (es)
CA (1) CA2088492A1 (es)
DE (1) DE69129459T2 (es)
DK (1) DK0542860T3 (es)
ES (1) ES2118087T3 (es)
GR (1) GR3027668T3 (es)
HK (1) HK1011503A1 (es)
WO (1) WO1992002229A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9217116D0 (en) * 1992-08-13 1992-09-23 Smithkline Beecham Corp Methods
GB9217121D0 (en) * 1992-08-13 1992-09-23 Smithkline Beecham Corp Methods
EP0605161A3 (en) * 1992-12-29 1994-10-05 American Home Prod Lowering the rheumatoid factor level.
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
EP1475091A1 (en) * 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5843936A (en) * 1996-06-28 1998-12-01 Bernstein; Lawrence R. Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes
DE19728436A1 (de) * 1997-07-03 1999-01-07 Niels Franke Niedrigdosierte 15-Desoxyspergualin-Präparate
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Also Published As

Publication number Publication date
JPH06500321A (ja) 1994-01-13
GR3027668T3 (en) 1998-11-30
DE69129459T2 (de) 1998-10-15
CA2088492A1 (en) 1992-02-11
HK1011503A1 (en) 1999-07-09
EP0542860B1 (en) 1998-05-20
WO1992002229A1 (en) 1992-02-20
DK0542860T3 (da) 1999-02-15
AU8412091A (en) 1992-03-02
JP2675194B2 (ja) 1997-11-12
DE69129459D1 (de) 1998-06-25
EP0542860A1 (en) 1993-05-26
ATE166228T1 (de) 1998-06-15
KR100215167B1 (ko) 1999-08-16
AU658577B2 (en) 1995-04-27
EP0542860A4 (en) 1993-08-04

Similar Documents

Publication Publication Date Title
DE69129459D1 (de) Immunosuppressive zusammensetzungen
PT951473E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
MX9300141A (es) Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FI980341A0 (fi) 2-oksi-indolijohdannaisia
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
LU90987I2 (fr) Copaxone et ses dérivés pharmaceutiquement acceptables
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES2097297T3 (es) Isoquinolein-5-il-sulfonamidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
MX9204563A (es) Nuevos derivados de la (2-alquil-3-piridil)-metilpiperazina y composicion farmaceutica que los comprende.
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
IT8867891A0 (it) Derivati terziobutilati di benzilidene canfora procedimento per la loro preparazione,loro impiego come agenti anti ossidanti e composizioni cosmetiche e farmaceutiche che li contengono
DE3875611D1 (de) Pharmazeutische zusammensetzungen.
ES2164168T3 (es) Antagonistas de receptores de fibrinogeno que tienen residuos de beta-aminoacido sustituidos y composiciones farmaceuticas que comprenden los mismos.
ES2191657T3 (es) Azaspiranos inmunomoduladores.
KR910002792A (ko) 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 542860

Country of ref document: ES